Xeris Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Xeris Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).
Xeris Pharmaceuticals: 14 sponsored US clinical trials, none currently recruiting.
Xeris Pharmaceuticals sponsors 14 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 4 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypoglycemia, with 3 trials.
Top-decile sponsor footprint
Xeris Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
14 total, page 1 of 1
Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
NCT05823012
Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D
NCT04074317
Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery
NCT03770637
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
NCT03738865
Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses
NCT03490942
G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes
NCT03439072
Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients
NCT03091673
Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics
NCT02656069
CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
NCT02937558
Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients
NCT02733588
G-Pen™ for Hypoglycemia Rescue in T1D Patients
NCT02423980
PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients
NCT02081001
Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes
NCT02081014
Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia
NCT01972152
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 10 |
| Phase 3 | 4 |
How the Xeris Pharmaceuticals early-phase archive is shaped
14 indexed studies, none listed as recruiting (0% open); 13 completed (93%).
Phase mix: 4 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Hypoglycemia (3 trials), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Xeris Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 14 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Xeris Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 14 archived trials
- 3-C Institute for Social Development · 14 trials · 0% recruiting
- Abbott Medical Optics · 14 trials · 0% recruiting
- Abbott RDx Cardiometabolic · 14 trials · 0% recruiting
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · 14 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Xeris Pharmaceuticals page
14 registered trials is a research-attention snapshot, not an endorsement of Xeris Pharmaceuticals or any single study.
- None of Xeris Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Hypoglycemia is the condition Xeris Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypoglycemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Xeris Pharmaceuticals pipeline card: 14 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.